Search company, investor...

Predict your next investment

Versant Ventures company logo
Venture Capital
versantventures.com

Investments

564

Portfolio Exits

125

Funds

28

Partners & Customers

6

Service Providers

2

About Versant Ventures

Versant Ventures is a healthcare investment firm committed to helping entrepreneurs build the healthcare companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $1.9 billion under management and offices in North America and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building.

Headquarters Location

One Sansome Street Suite 3630

San Francisco, California, 94104,

United States

415-801-8100

Want to inform investors similar to Versant Ventures about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing Versant Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Versant Ventures in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

382 items

Research containing Versant Ventures

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Versant Ventures in 1 CB Insights research brief, most recently on Feb 2, 2021.

Latest Versant Ventures News

Pierre Fabre Laboratories acquires Vertical Bio AG

Sep 17, 2023

Pierre Fabre Laboratories acquires Vertical Bio AG 14 September 2023 – Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. Vertical Bio was founded by Versant Ventures and was launched out of the firm's Ridgeline Discovery Engine based in Basel, Switzerland. Leveraging Ridgeline's biology capabilities, Vertical Bio advanced VERT-002 through preclinical studies and towards an IND submission. The first-in-human studies are expected to begin in 2024. Walder Wyss advised Versant Ventures on this transaction. The team included Alexander Gutmans (Partner, Corporate/M&A), Lucas Maurer (Associate, Corporate/M&A), Simon Olstein (Associate, Corporate/M&A), Karina Tschon (Senior Associate, Corporate/M&A) and Michelle Bruni (Managing Associate, Corporate/M&A and Tax). Walder Wyss Ltd.

Versant Ventures Investments

564 Investments

Versant Ventures has made 564 investments. Their latest investment was in Tentarix Biotherapeutics as part of their Series B on September 9, 2023.

CBI Logo

Versant Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/6/2023

Series B

Tentarix Biotherapeutics

$35M

No

2

8/21/2023

PIPE

Skye Bioscience

$12M

Yes

5AM Ventures, Undisclosed Investors, and Versant Ventures

2

7/26/2023

Series A

Nexo Therapeutics

$60M

No

1

7/11/2023

Series C

Subscribe to see more

$99M

Subscribe to see more

10

6/8/2023

Series A

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/6/2023

8/21/2023

7/26/2023

7/11/2023

6/8/2023

Round

Series B

PIPE

Series A

Series C

Series A

Company

Tentarix Biotherapeutics

Skye Bioscience

Nexo Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$35M

$12M

$60M

$99M

$99M

New?

No

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

5AM Ventures, Undisclosed Investors, and Versant Ventures

Sources

2

2

1

10

10

Versant Ventures Portfolio Exits

125 Portfolio Exits

Versant Ventures has 125 portfolio exits. Their latest portfolio exit was RayzeBio on September 15, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/15/2023

IPO

$99M

Public

3

8/21/2023

Acquired

$99M

2

8/8/2023

Acquired

$99M

4

7/21/2023

IPO

Subscribe to see more

$99M

Subscribe to see more

10

1/17/2023

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/15/2023

8/21/2023

8/8/2023

7/21/2023

1/17/2023

Exit

IPO

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

3

2

4

10

10

Versant Ventures Fund History

28 Fund Histories

Versant Ventures has 28 funds, including Versant Venture Capital VIII.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/21/2021

Versant Venture Capital VIII

$560M

1

4/21/2021

Versant Vantage II

$240M

2

11/18/2020

Versant Venture Capital VII

$600M

3

8/13/2019

Versant Voyageurs I

Subscribe to see more

Subscribe to see more

$99M

10

4/24/2018

Versant Voyageurs I Feeder

$99M

10

Closing Date

4/21/2021

4/21/2021

11/18/2020

8/13/2019

4/24/2018

Fund

Versant Venture Capital VIII

Versant Vantage II

Versant Venture Capital VII

Versant Voyageurs I

Versant Voyageurs I Feeder

Fund Type

Subscribe to see more

Status

Subscribe to see more

Amount

$560M

$240M

$600M

$99M

$99M

Sources

1

2

3

10

10

Versant Ventures Partners & Customers

6 Partners and customers

Versant Ventures has 6 strategic partners and customers. Versant Ventures recently partnered with AbCellera on July 7, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

7/27/2022

Licensor

Canada

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

Versant Ventures and AbCellera Biologics Inc. already have enabled three of the firm 's stealth-stage companies under previous partnerships .

4

11/30/2021

Partner

United States

Subscribe to see more

Subscribe to see more

10

2/15/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

12/12/2016

Partner

Germany

Subscribe to see more

Subscribe to see more

10

6/23/2014

Partner

United States, and Switzerland

Subscribe to see more

Subscribe to see more

10

Date

7/27/2022

11/30/2021

2/15/2017

12/12/2016

6/23/2014

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

Country

Canada

United States

United States

Germany

United States, and Switzerland

News Snippet

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

Versant Ventures and AbCellera Biologics Inc. already have enabled three of the firm 's stealth-stage companies under previous partnerships .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Versant Ventures Service Providers

2 Service Providers

Versant Ventures has 2 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

General Counsel

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Associated Rounds

Provider Type

Counsel

Subscribe to see more

Service Type

General Counsel

Subscribe to see more

Partnership data by VentureSource

Versant Ventures Team

24 Team Members

Versant Ventures has 24 team members, including current Founder, Managing Director, Brian G Atwood.

Name

Work History

Title

Status

Brian G Atwood

Founder, Managing Director

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Brian G Atwood

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Director

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.